Drug intelligence / Profile preview

G262-CD19-CAR

Development stage: Unknown
Lead developer: Formula 1
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Subcutaneous

Overview

G262-CD19-CAR is an autologous, CD19-targeted CAR-T cell therapy developed by Exuma Biotechnology using its proprietary rapid point-of-care subcutaneous (rPOC SC) platform. This innovative approach involves a streamlined, single-day manufacturing process with a four-hour lentiviral vector uptake, bypassing the need for traditional multi-week production and lymphodepleting chemotherapy. Administered subcutaneously, the therapy is designed to create synthetic lymph nodes at the injection site that serve as 'CAR factories,' generating CAR-TaNK cells (cells with both T and NK-like properties) within the patient's body. G262-CD19-CAR is currently being evaluated for the treatment of Large B-Cell Lymphoma (LBCL) and various autoimmune diseases, aiming to improve the safety, scalability, and accessibility of CAR-T cell therapies.

Other names: CD19-CAR-T cell therapy (rPOC SC platform)

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on G262-CD19-CAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G262-CD19-CAR.

Explore the full profile